Studies of low-intensity induction for adults with Ph+ ALL
| Study . | Induction . | N . | Age, median (range), y . | CR, % . | IM, % . |
|---|---|---|---|---|---|
| LAL0201-B46 | Imatinib + prednisone | 29 | 69 (61-83) | 100 | 0 |
| LAL12057 | Dasatinib + prednisone | 53 | 54 (24-77) | 100 | 0 |
| EWALL-Ph0143 | Dasatinib, vincristine, dexamethasone | 91 | 69 | 96 | 4 |
| CALGB 107016 | Dasatinib + dexamethasone | 64 | 60 (22-87) | 97 | 0 |
| EWALL-Ph0258 | Nilotinib, vincristine, dexamethasone | 72 | 65.5 | 94 | 1.3 |
| LAL181147 | Ponatinib + prednisone | 42 | 68 (27-85) | 95 | 2.3 |
| Study . | Induction . | N . | Age, median (range), y . | CR, % . | IM, % . |
|---|---|---|---|---|---|
| LAL0201-B46 | Imatinib + prednisone | 29 | 69 (61-83) | 100 | 0 |
| LAL12057 | Dasatinib + prednisone | 53 | 54 (24-77) | 100 | 0 |
| EWALL-Ph0143 | Dasatinib, vincristine, dexamethasone | 91 | 69 | 96 | 4 |
| CALGB 107016 | Dasatinib + dexamethasone | 64 | 60 (22-87) | 97 | 0 |
| EWALL-Ph0258 | Nilotinib, vincristine, dexamethasone | 72 | 65.5 | 94 | 1.3 |
| LAL181147 | Ponatinib + prednisone | 42 | 68 (27-85) | 95 | 2.3 |